A large study on the use of the antimalaria drug hydroxychloroquine in hospitalized COVID-19 patients found that the drug had no impact on the risk of the most severe outcomes from the diseaseThe observational study, published yesterday in the New England Journal of Medicine, looked at data on nearly 1,400 patients treated for COVID-19 at a large hospital in New York City, more than half of whom received hydroxychloroquine.
Analysis of patient outcomes showed that the risk of intubation or death was not significantly higher or lower among patients who received the drug than among those who did not.The authors of the study say the results should not be taken to rule out either benefit or harm from hydroxychloroquine, which is currently being